Metformin Is Associated With Survival Benefit in Cancer Patients With Concurrent Type 2 Diabetes: A Systematic Review and Meta-Analysis
Open accessThe DOI matches its Crossref record; 54 of the 55 references it cites were found in a registry or an index.
Abstract
Learning Objectives: Describe the influences of different types of glucose-lowering medications on therapeutic outcomes of cancer patients who received standard anticancer treatment. Compare the survival associated with metformin treatment with survival in treatment with other glucose-lowering medications.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“In human cancer patients with diabetes, metformin was associated with a decrease in 2-year mortality compared with other glucose-lowering medications (88).”
From Cellular Senescence in Type 2 Diabetes: A Therapeutic Opportunity (2015) · cites this paper as [88]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Duval, S., & Tweedie, R. (2000) · Biometrics · doi:10.1111/j.0006-341x.2000.00455.x · Cited by 14,099
Practical methods for incorporating summary time-to-event data into meta-analysis.
Tierney, J. F., Stewart, L. A., Ghersi, D., Burdett, S., & Sydes, M. R. (2007) · Trials · doi:10.1186/1745-6215-8-16 · Cited by 6,208
Giovannucci, E., Harlan, D. M., Archer, M. C., Bergenstal, R. M., Gapstur, S. M., Habel, L. A., Pollak, M., Regensteiner, J. G., & Yee, D. (2010) · Diabetes Care · doi:10.2337/dc10-0666 · Cited by 2,366
Foretz, M., Hébrard, S., Leclerc, J., Zarrinpashneh, E., Soty, M., Mithieux, G., Sakamoto, K., Andreelli, F., & Viollet, B. (2010) · Journal of Clinical Investigation · doi:10.1172/jci40671 · Cited by 1,181
Metformin is an AMP kinase-dependent growth inhibitor for breast cancer cells
Zakikhani, M., Dowling, R., Fantus, I. G., Sonenberg, N., & Pollak, M. (2006) · Cancer Research · doi:10.1158/0008-5472.can-06-1500 · Cited by 1,048
Dowling, R. J. O., Zakikhani, M., Fantus, I. G., Pollak, M., & Sonenberg, N. (2007) · Cancer Research · doi:10.1158/0008-5472.can-07-2310 · Cited by 933
Bowker, S. L., Majumdar, S. R., Veugelers, P., & Johnson, J. A. (2006) · Diabetes Care · doi:10.2337/diacare.29.02.06.dc05-1558 · Cited by 933
Metformin, independent of AMPK, inhibits mTORC1 in a rag GTPase-dependent manner
Kalender, A., Selvaraj, A., Kim, S. Y., Gulati, P., Brûlé, S., Viollet, B., Kemp, B. E., Bardeesy, N., Dennis, P., Schlager, J. J., et al. (2010) · Cell Metabolism · doi:10.1016/j.cmet.2010.03.014 · Cited by 889
Jiralerspong, S., Palla, S. L., Giordano, S. H., Meric-Bernstam, F., Liedtke, C., Barnett, C. M., Hsu, L., Hung, M.-C., Hortobagyi, G. N., & Gonzalez-Angulo, A. M. (2009) · Journal of Clinical Oncology · doi:10.1200/jco.2009.19.6410 · Cited by 880
Adjusting for publication bias in the presence of heterogeneity
Terrin, N., Schmid, C. H., Lau, J., & Olkin, I. (2003) · Statistics in Medicine · doi:10.1002/sim.1461 · Cited by 809
Peters, J. L., Sutton, A. J., Jones, D. R., Abrams, K. R., & Rushton, L. (2007) · Statistics in Medicine · doi:10.1002/sim.2889 · Cited by 716
Metformin, independent of AMPK, induces mTOR inhibition and cell-cycle arrest through REDD1
Ben Sahra, I., Regazzetti, C., Robert, G., Laurent, K., Le Marchand-Brustel, Y., Auberger, P., Tanti, J.-F., Giorgetti-Peraldi, S., & Bost, F. (2011) · Cancer Research · doi:10.1158/0008-5472.can-10-1769 · Cited by 616
Cancer risk in diabetic patients treated with metformin: a systematic review and meta-analysis
Noto, H., Goto, A., Tsujimoto, T., & Noda, M. (2012) · PLoS ONE · doi:10.1371/journal.pone.0033411 · Cited by 566
Alimova, I. N., Liu, B., Fan, Z., Edgerton, S. M., Dillon, T., Lind, S. E., & Thor, A. D. (2009) · Cell Cycle · doi:10.4161/cc.8.6.7933 · Cited by 523
Iliopoulos, D., Hirsch, H. A., & Struhl, K. (2011) · Cancer Research · doi:10.1158/0008-5472.can-10-3471 · Cited by 450
Kim, Y. D., Park, K.-G., Lee, Y.-S., Park, Y.-Y., Kim, D.-K., Nedumaran, B., Jang, W. G., Cho, W.-J., Ha, J., Lee, I.-K., et al. (2008) · Diabetes · doi:10.2337/db07-0381 · Cited by 422
Mortality After Incident Cancer in People With and Without Type 2 Diabetes
Currie, C. J., Poole, C. D., Jenkins-Jones, S., Gale, E. A. M., Johnson, J. A., & Morgan, C. L. (2012) · Diabetes Care · doi:10.2337/dc11-1313 · Cited by 398
Chen, H.-P., Shieh, J.-J., Chang, C.-C., Chen, T.-T., Lin, J.-T., Wu, M.-S., Lin, J.-H., & Wu, C.-Y. (2013) · Gut · doi:10.1136/gutjnl-2011-301708 · Cited by 392
Safety issues and prospects for future generations of PPAR modulators
RUBENSTRUNK, A., HANF, R., HUM, D., FRUCHART, J., & STAELS, B. (2007) · Biochimica et Biophysica Acta (BBA) - Molecular and Cell Biology of Lipids · doi:10.1016/j.bbalip.2007.02.003 · Cited by 309
Metformin Use Is Associated with Better Survival of Diabetic Patients with Pancreatic Cancer
Sadeghi, N., Abbruzzese, J. L., Yeung, S.-C. J., Hassan, M., & Li, D. (2012) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-11-2994 · Cited by 305
Therapy Insight: influence of type 2 diabetes on the development, treatment and outcomes of cancer
Richardson, L. C., & Pollack, L. A. (2005) · Nature Clinical Practice Oncology · doi:10.1038/ncponc0062 · Cited by 289
Cancer Risk Associated with Use of Metformin and Sulfonylurea in Type 2 Diabetes: A Meta-Analysis
Soranna, D., Scotti, L., Zambon, A., Bosetti, C., Grassi, G., Catapano, A., La Vecchia, C., Mancia, G., & Corrao, G. (2012) · The Oncologist · doi:10.1634/theoncologist.2011-0462 · Cited by 274
Metformin elicits anticancer effects through the sequential modulation of DICER and c-MYC
Blandino, G., Valerio, M., Cioce, M., Mori, F., Casadei, L., Pulito, C., Sacconi, A., Biagioni, F., Cortese, G., Galanti, S., et al. (2012) · Nature Communications · doi:10.1038/ncomms1859 · Cited by 242
He, X., Esteva, F. J., Ensor, J., Hortobagyi, G. N., Lee, M.-H., & Yeung, S.-C. J. (2012) · Annals of Oncology · doi:10.1093/annonc/mdr534 · Cited by 207
Dual antiglioma action of metformin: cell cycle arrest and mitochondria-dependent apoptosis
Isakovic, A., Harhaji, L., Stevanovic, D., Markovic, Z., Sumarac-Dumanovic, M., Starcevic, V., Micic, D., & Trajkovic, V. (2007) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-007-7080-4 · Cited by 204
The effects of metformin on the survival of colorectal cancer patients with diabetes mellitus
Lee, J. H., Kim, T. I., Jeon, S. M., Hong, S. P., Cheon, J. H., & Kim, W. H. (2012) · International Journal of Cancer · doi:10.1002/ijc.26421 · Cited by 204
Spratt, D. E., Zhang, C., Zumsteg, Z. S., Pei, X., Zhang, Z., & Zelefsky, M. J. (2013) · European Urology · doi:10.1016/j.eururo.2012.12.004 · Cited by 180
Romero, I. L., McCormick, A., McEwen, K. A., Park, S., Karrison, T., Yamada, S. D., Pannain, S., & Lengyel, E. (2012) · Obstetrics & Gynecology · doi:10.1097/aog.0b013e3182393ab3 · Cited by 177
Bayraktar, S., Hernadez‐Aya, L. F., Lei, X., Meric‐Bernstam, F., Litton, J. K., Hsu, L., Hortobagyi, G. N., & Gonzalez‐Angulo, A. M. (2012) · Cancer · doi:10.1002/cncr.26439 · Cited by 176
Tan, B., Yao, W., Ge, J., Peng, X., Du, X., Zhang, R., Yao, B., Xie, K., Li, L., Dong, H., et al. (2011) · Cancer · doi:10.1002/cncr.26151 · Cited by 163
He, X., Tu, S., Lee, M., & Yeung, S. J. (2011) · Annals of Oncology · doi:10.1093/annonc/mdr020 · Cited by 161
Meta-Analysis of Genome-wide Association Studies with Overlapping Subjects
Lin, D.-Y., & Sullivan, P. F. (2009) · The American Journal of Human Genetics · doi:10.1016/j.ajhg.2009.11.001 · Cited by 160
Metformin intake is associated with better survival in ovarian cancer: A case‐control study
Kumar, S., Meuter, A., Thapa, P., Langstraat, C., Giri, S., Chien, J., Rattan, R., Cliby, W., & Shridhar, V. (2013) · Cancer · doi:10.1002/cncr.27706 · Cited by 160
Garrett, C. R., Hassabo, H. M., Bhadkamkar, N. A., Wen, S., Baladandayuthapani, V, Kee, B. K., Eng, C., & Hassan, M. M. (2012) · British Journal of Cancer · doi:10.1038/bjc.2012.71 · Cited by 152
Nobes, J. P., Langley, S. E. M., Klopper, T., Russell-Jones, D. L., & Laing, R. W. (2011) · British Journal of Urology · doi:10.1111/j.1464-410x.2011.10555.x · Cited by 132
The effect of metformin and thiazolidinedione use on lung cancer in diabetics
Mazzone, P. J., Rai, H., Beukemann, M., Xu, M., Jain, A., & Sasidhar, M. (2012) · BMC Cancer · doi:10.1186/1471-2407-12-410 · Cited by 112
Association Between Metformin Therapy and Mortality After Breast Cancer
Lega, I. C., Austin, P. C., Gruneir, A., Goodwin, P. J., Rochon, P. A., & Lipscombe, L. L. (2013) · Diabetes Care · doi:10.2337/dc12-2535 · Cited by 110
Chen, T., Lin, C., Huang, P., & Wen, C. (2011) · Journal of Gastroenterology and Hepatology · doi:10.1111/j.1440-1746.2011.06664.x · Cited by 107
Fidan, E., Ersöz, H. Ö., Yılmaz, M., Yilmaz, H., Koçak, M., Karahan, C., & Erem, C. (2011) · Acta Diabetologica · doi:10.1007/s00592-011-0276-y · Cited by 106
Hou, G., Zhang, S., Zhang, X., Wang, P., Hao, X., & Zhang, J. (2013) · Breast Cancer Research and Treatment · doi:10.1007/s10549-012-2404-y · Cited by 100
Metformin inhibits renal cell carcinoma in vitro and in vivo xenograft
Liu, J., Li, M., Song, B., Jia, C., Zhang, L., Bai, X., & Wei-lie, H. (2011) · Urologic Oncology Seminars and Original Investigations · doi:10.1016/j.urolonc.2011.01.003 · Cited by 98
A Cohort Study of Metformin Exposure and Survival in Patients with Stage I–III Colorectal Cancer
Spillane, S., Bennett, K., Sharp, L., & Barron, T. I. (2013) · Cancer Epidemiology, Biomarkers & Prevention · doi:10.1158/1055-9965.epi-13-0347 · Cited by 91
Clinical Outcomes After Radical Prostatectomy in Diabetic Patients Treated With Metformin
Patel, T., Hruby, G. W., Badani, K. K., Abate-Shen, C. T., & McKiernan, J. M. (2010) · Urology · doi:10.1016/j.urology.2010.03.059 · Cited by 90
Luo, Q., Hu, D., Hu, S., Yan, M., Sun, Z., & Chen, F. (2012) · BMC Cancer · doi:10.1186/1471-2407-12-517 · Cited by 90
Bulc??o, C., Ribeiro‐Filho, F. F., Sañudo, A., & Ferreira, S. G. R. (2007) · American Journal of Cardiovascular Drugs · doi:10.2165/00129784-200707030-00007 · Cited by 74
Sandulache, V. C., Hamblin, J. S., Skinner, H. D., Kubik, M. W., Myers, J. N., & Zevallos, J. P. (2013) · Head & Neck · doi:10.1002/hed.23409 · Cited by 66
Nakai, Y., Isayama, H., Sasaki, T., Mizuno, S., Sasahira, N., Kogure, H., Kawakubo, K., Yamamoto, N., Hirano, K., Ijichi, H., et al. (2013) · Pancreas · doi:10.1097/mpa.0b013e31825de678 · Cited by 63
Diabetes, metformin use, and colorectal cancer survival in postmenopausal women
Cossor, F. I., Adams-Campbell, L. L., Chlebowski, R. T., Gunter, M. J., Johnson, K., Martell, R. E., McTiernan, A., Simon, M. S., Rohan, T., Wallace, R. B., et al. (2013) · Cancer Epidemiology · doi:10.1016/j.canep.2013.04.015 · Cited by 60
Effect of metformin on prostate cancer outcomes after radical prostatectomy
Kaushik, D., Karnes, R. J., Eisenberg, M. S., Rangel, L. J., Carlson, R. E., & Bergstralh, E. J. (2013) · Urologic Oncology Seminars and Original Investigations · doi:10.1016/j.urolonc.2013.05.005 · Cited by 58
Zhang, F., Yang, Y., Skrip, L., Hu, D., Wang, Y., Wong, C., Qiu, J., & Lei, H. (2012) · Acta Diabetologica · doi:10.1007/s00592-012-0439-5 · Cited by 57
Tseng, S.-C., Huang, Y., Chen, H.-J., Chiu, H., Huang, Y., Wo, T., Weng, S., & Lin, Y. (2012) · Biochemical Pharmacology · doi:10.1016/j.bcp.2012.12.001 · Cited by 57
Metformin and pioglitazone: effectively treating insulin resistance
Staels, B. (2006) · Current Medical Research and Opinion · doi:10.1185/030079906x112732 · Cited by 53
Koo, Y. X., Tan, D. S.-W., Tan, I. B. H., Tai, D. W.-M., Ha, T., Ong, W. S., Quek, R. H. H., Tao, M., & Lim, S. T. (2011) · Leukemia & lymphoma/Leukemia and lymphoma · doi:10.3109/10428194.2011.574752 · Cited by 28
Lee, D.-J., Kim, B., Lee, J. H., Park, S. J., Hong, S. P., Cheon, J. H., Kim, T. I., & Kim, W. H. (2012) · Korean Journal of Gastroenterology · doi:10.4166/kjg.2012.60.6.355 · Cited by 17
Research works printed but not linked: 1
- Sandulache, 2013, Metformin use is associated with improved survival in patients with laryngeal squamous cell carcinoma, Head Neck
Cited by
Update on the treatment of type 2 diabetes mellitus
Marín-Peñalver, J. J., Martín-Timón, I., Sevillano-Collantes, C., & Cañizo-Gómez, F. J. D. (2016) · World Journal of Diabetes · doi:10.4239/wjd.v7.i17.354 · Cited by 647
“In different meta-analyses in T2DM patients, use of metformin compared with non-use or with use of other diabetes treatment, was related with a reduced risk of all cancers and lower cancer mortality [69,70] .”
MethodMetformin as an adjuvant treatment for cancer: a systematic review and meta-analysis
Coyle, C., Cafferty, F. H., Vale, C., & Langley, R. E. (2016) · Annals of Oncology · doi:10.1093/annonc/mdw410 · Cited by 452
Cellular Senescence in Type 2 Diabetes: A Therapeutic Opportunity
Palmer, A. K., Tchkonia, T., LeBrasseur, N. K., Chini, E. N., Xu, M., & Kirkland, J. L. (2015) · Diabetes · doi:10.2337/db14-1820 · Cited by 423
“In human cancer patients with diabetes, metformin was associated with a decrease in 2-year mortality compared with other glucose-lowering medications (88).”
BackgroundPhase II Study of Everolimus and Letrozole in Patients With Recurrent Endometrial Carcinoma
Slomovitz, B. M., Jiang, Y., Yates, M. S., Soliman, P. T., Johnston, T., Nowakowski, M., Levenback, C., Zhang, Q., Ring, K., Munsell, M. F., et al. (2015) · Journal of Clinical Oncology · doi:10.1200/jco.2014.58.3401 · Cited by 324
Drug repurposing in oncology—patient and health systems opportunities
Bertolini, F., Sukhatme, V. P., & Bouche, G. (2015) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2015.169 · Cited by 294
Metadata
- Authors
- Yin, M., Zhou, J., Gorak, E. J., & Quddus, F.
- Affiliations
- Department of Internal Medicine, Danville, Pennsylvania, USA
- Geisinger Medical Center (US)
- Corresponding author
- Yin, Ming
- Quddus, Fahd
- Venue
- The Oncologist
- Publisher
- Oxford University Press (OUP)
- Published
- 2013-11-20
- Volume
- 18
- Issue
- 12
- Pages
- 1248-1255
- ISSN
- 1083-7159 (ISSN-L)
- 1549-490X
- PMC
- PMC3868417
- OpenAlex
- W2146511561
- Cited by
- 157
- References
- 55
- Citations by year
- 2026: 2 · 2025: 8 · 2024: 5 · 2023: 10 · 2022: 9 · 2021: 15 · 2020: 16 · 2019: 7 · 2018: 11 · 2017: 13 · 2016: 22 · 2015: 22 · 2014: 16 · 2013: 1
- FWCI
- 1.91
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Licence
- academic.oup.com/journals/pages/open_access/funder_policies/chorus/standard_publication_model (vor)
- Locations
- The Oncologist (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Metabolism, Diabetes, and Cancer
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Cancer, Hypoxia, and Metabolism
- Keywords
- metformin, type 2 diabetes, cancer, overall survival, cancer-specific survival, glucose-lowering medications, cancer mortality, drug repurposing
- MeSH terms
- Diabetes Mellitus, Type 2, Humans, Hypoglycemic Agents, Metformin, Neoplasms
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.